MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir
ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.
ViiV Healthcare | 15/07/2025 | By Dineshwori | 141
Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries under voluntary licence from ViiV Healthcare
ViiV Healthcare | 17/08/2023 | By Sudeep Soparkar | 485
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy